• Susan R Vishneski, Amit K Saha, Madeline R Fram, Leah B Templeton, Lisa K Lee, Douglas G Ririe, Eduardo Javier Goenaga-Diaz, Laura Daniela Smith, and TempletonThomas WesleyTW0000-0002-7665-8138Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA..
• Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
• Paediatr Anaesth. 2022 Aug 1; 32 (8): 916-925.

BackgroundThe prevalence and risk factors for residual neuromuscular blockade in children remain poorly characterized. We hypothesize that specific patient and anesthetic risk factors may be associated with the administration of additional reversal in children following initial reversal of rocuronium with neostigmine.MethodsOur electronic health record was queried for patients <18 years of age who received rocuronium and reversal with neostigmine from 2017 through 2020. Patients receiving other nondepolarizing neuromuscular blocking drugs were excluded. The outcome of interest was defined as the administration of additional neostigmine or sugammadex following primary reversal with neostigmine. Time between the last dose of rocuronium and initial dose of neostigmine, and the cumulative dose of rocuronium were dichotomized. These were combined with other covariates including age, weight, sex, racial group, procedure type, ASA physical status, >1 rocuronium dose administered during the procedure, initial neostigmine dose <0.05 mg kg-1 , use of train-of-four monitoring, duration of anesthesia, inpatient or outpatient, emergency case, neuromuscular disease, and extremes of weight, to assess possible associations with the primary outcome.ResultsDuring the study period, 101/6373 (1.58%) patients received rocuronium and additional reversal. Dichotomization of time between last dose of rocuronium and neostigmine yielded <28 min since the last dose of rocuronium and cumulative dose of rocuronium >0.45 mg kg-1  hr-1 . These were associated with the administration of additional reversal with an OR 1.52 (95% CI, 1.08-2.35) and OR 1.71 (95% CI, 1.10-2.67), respectively. Other risk factors included an initial neostigmine dose <0.05 mg kg-1 , OR 4.98 (95% CI, 2.84-6.49), and African American race, OR 1.78 (95% CI, 1.07-2.87).ConclusionRisk factors associated with the administration of additional reversal included time <28 min from the last dose of rocuronium to initial dose of neostigmine, cumulative dose of rocuronium >0.45 mg kg-1  hr-1 , initial neostigmine dose <0.05 mg kg-1 , and African American race.© 2022 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd.

21 keywords...

hide…